<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00545077</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM/2006-11/GBG 51</org_study_id>
    <secondary_id>2007-002841-19</secondary_id>
    <nct_id>NCT00545077</nct_id>
  </id_info>
  <brief_title>Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women</brief_title>
  <official_title>Multicenter, Randomized Trial to Evaluate Efficacy and Safety of Bevacizumab in Combination With Endocrine Treatment vs Endocrine Alone, in Postmenopausal With Advanced or Metastatic Cancer With Indication of Hormonotherapy as First-line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Locally advanced or metastatic breast cancer in postmenopausal women with negative Human
      Epidermal Growth Factor Receptor 2 (HER2), who are candidates for hormone treatment and who
      have not received previous chemotherapy or hormonotherapy for the metastatic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main endpoint of the study is progression-free survival (PFS). It has been calculated
      that 378 patients will need to be included, according to the following assumptions:

        -  Recruitment period of 21 months.

        -  Minimum follow-up period of 9 months.

        -  PFS of 9 months in the control arm (letrozole in monotherapy). Using a two-sided
           log-rank test, for a 5% α level, 344 patients (172 in each treatment arm) will be
           required for 270 events to occur, which will provide an 80% power for detecting a hazard
           ratio of 0.69 (corresponding to a PFS median of 13 months in the bevacizumab arm). This
           sample size has been adjusted for an intermediate analysis when 2/3 of the total of
           required events have occurred. This intermediate analysis can be avoided if, at the time
           in which it must be carried out, it is estimated that the final analysis will be carried
           out in 4 months.

      Taking into account a 10% percentage of losses, 378 patients are expected to be included in
      the study.

      An intermediate safety evaluation will be carried out when 63 patients have finished their
      treatment in each treatment arm.

      A multicenter, randomized phase III clinical trial. After verifying the selection criteria,
      the patients will be randomized to receive letrozole alone or in combination with
      bevacizumab. Before randomization, the patients will be stratified according to the following
      prognosis factors:

        -  Estrogen Receptor (ER)+ / Progesterone Receptor (PgR)+ vs the other options (ER+/PgR- vs
           ER-/PgR+)

        -  Previous adjuvant hormonotherapy (yes/no)

        -  Status: locally advanced vs metastatic.

        -  Measurable vs non measurable disease

        -  Visceral disease (yes/no)

        -  PFS.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2007</start_date>
  <completion_date type="Actual">July 24, 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS was defined as the time elapsed from randomization until the date in which the progression of the disease or the death for any reason (whichever occurs first) is documented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS was defined as the time elapsed since randomization, until the time in which death occurs for any reason. The patients lost in the follow-up will be censured at the date of the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TTF was defined as the time elapsed since randomization until the date the treatment is discontinued for any reason (progression disease, treatment toxicity or death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>ORR to treatment is reflected by a frequency table containing the data of the best overall response (Complete Response, Partial Response,Stable Disease or Progressive Disease) experienced for each patient during treatment (recorded from the start of the treatment until disease progression) per arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Duration (RD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>RD was defined as the time elapsed from when a partial or complete response is verified until the time in which progression or death occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>CBR was defined as the percentage of patients achieving a Complete Response (CR), a Partial Response (PR) or a stabilization of the disease (SD) &gt; 6 months: the response will be evaluated according to the RECIST criteria. In the patients without measurable disease at the baseline time, the clinical benefit will be defined as the absence of progression &gt; 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Endocrine Therapy (ET)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: ET with Bevacizumab (ET-B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Arm A: Endocrine Therapy (ET)</arm_group_label>
    <arm_group_label>Arm B: ET with Bevacizumab (ET-B)</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Arm B: ET with Bevacizumab (ET-B)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Arm A: Endocrine Therapy (ET)</arm_group_label>
    <arm_group_label>Arm B: ET with Bevacizumab (ET-B)</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Before starting the specific protocol procedures, the written informed consent must be
             obtained and documented.

          2. Women ≥ 18 years.

          3. Capacity to comply with all the protocol requirements.

          4. Functional Eastern Cooperative Oncology Group (ECOG) status of 0 or 1.

          5. Life expectancy ≥ 24 weeks.

          6. Histologically confirmed breast adenocarcinoma, with measurable or non-measurable,
             locally advanced or metastatic (stage IV) disease. In the event that the patient only
             has locally advanced disease, she will not be able to undergo curative local
             treatment. Patients with metastasis confined to the bone can be chosen, but the
             disease must be confirmed by radiology, CT scan or Nuclear magnetic resonance (NMR) if
             there is any doubt after a single bone scan.

          7. Patients with HER2-negative disease evaluated by Immunohistochemistry (IHC) and
             Fluorescence in situ hybridization (FISH)/Chromogenic in situ hybridisation (CISH)
             (IHC 0 or 1+, or 2+ and negative FISH). Patients with 3+ by IHC cannot be chosen
             regardless of the FISH/CISH status and those with positive FISH/CISH (&gt; 2
             amplifications) cannot be chosen either, regardless of the IHC findings.

          8. Positive hormone receptors (estrogen receptor [ER] and/or progesterone receptor [PgR])
             evaluated by a local or central laboratory, according to the criteria of the
             participating institution.

          9. Patients who are candidates for receiving first-line treatment with letrozole.

         10. Patients may have received (neo)adjuvant chemotherapy, provided that the last dose of
             the latter was received at least 12 months before randomization. Patients must be
             recovered from toxicity.

         11. The patients are allowed to have received adjuvant radiotherapy, provided that it was
             completed at least 6 weeks before randomization and the patient has recovered from the
             reversible acute effects of the radiation. The previous administration of radiotherapy
             to palliate the pain of bone metastases is authorized, provided that:

               -  Not more than 30% of bone marrow has been irradiated.

               -  The patient has recovered from the reversible acute effects of the radiation.

               -  The patient has at least one metastatic location which has not been irradiated
                  and which may be evaluated for progression, or a clear progression of the bone
                  disease has been objectified after the end of the palliative radiotherapy.

         12. The patients may have received any kind of previous (neo)adjuvant hormone therapy
             provided that they are considered to be candidates for first-line hormonotherapy with
             either letrozole or fulvestrant.

         13. The treatment with bisphosphonates is allowed and recommended for patients with bone
             metastases. Whenever it is possible, the treatment should be started before or within
             the 4 weeks of starting the study therapy. The patients starting treatment with
             bisphosphonates must be carefully evaluated so that they do not mask the progression
             of the disease.

         14. In the patients with heart failure risk (e.g. previously treated with &gt; 360mg/m2 of
             doxorubicin or equivalent doses of other anthracyclines), the Left Ventricular
             Ejection Fraction (LVEF) must be determined by means of an echocardiogram or
             radionuclide ventriculography (MUGA), and it must t be &gt; the lower limit of normal.

        Exclusion Criteria:

          1. Evolutionary disease requiring an immediate treatment with cytotoxic chemotherapy
             according to the investigator's judgment.

          2. Patients with locally advanced breast cancer who are expected to undergo surgery or
             curative radiotherapy.

          3. Previous chemotherapy or hormonotherapy for the metastatic disease. Patients may have
             received neoadjuvant chemotherapy or neoadjuvant hormonotherapy with curative
             intention as a part or as an alternative to an adjuvant treatment. For the previous
             neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are
             valid.

          4. Previous therapy with anti-vascular endothelial growth factor (VEGF) or VEGF Receptor
             (VEGFR) tyrosine-kinase inhibitors.

          5. History of another pathology that may affect the development of the protocol or the
             interpretation of results. It is considered that patients who have suffered from a
             skin carcinoma that is not melanoma, cervical carcinoma in situ or another neoplasia
             treated with a curative intention and with a disease-free interval exceeding 5 years
             can be chosen.

          6. Evidence of central nervous system (CNS) metastasis. A CT scan or brain NMR must be
             done within the 4 weeks before the randomization in case of suspecting brain
             metastasis.

          7. History or evidence in the physical or neurological examination of CNS pathology
             unrelated to cancer unless it is suitable treated with standard therapy (e.g.
             uncontrolled convulsions).

          8. History of peripheral neuropathy National Cancer Institute (NCI) CTCAE grade &gt;2 at the
             time of randomization.

          9. Patients subjected to major surgical procedures, open biopsies or those having
             significant trauma injuries within the 28 days prior to randomization, or patients who
             are expected to undergo a major surgical procedure that must necessarily be performed
             within the course of the study.

         10. Minor surgical procedures in the 7 days prior to randomization.

         11. Unsuitable bone marrow supply: absolute neutrophil count (ANC) &lt; 1.5 x 109/L,
             platelets &lt; 100 x 109/L or Hb &lt; 10 g/dL.

         12. Impaired liver function: total bilirubin total &gt; 1.5 x upper limit of normal (ULN),
             aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) &gt; 2.5 x ULN (&gt; 5 x
             ULN in patients with liver metastases).

         13. Impaired kidney function:

               1. Serum creatinine &gt; 2.0 mg/dL or 177 µmol/L.

               2. Proteinuria determined by reactive strip &gt; 2+. A 24h determination of proteins in
                  urine will be requested for the patients with &gt; 2+ in the baseline analysis and
                  must have a protein figure &lt; 1 g/24 h.

         14. Chronic treatment with oral corticoids (dose &gt; 10 mg/day of methylprednisolone or
             equivalent): the use of inhaled corticoids is allowed.

         15. Chronic treatment with acetylsalicylic acid (&gt; 325 mg/day) or clopidogrel (&gt; 75
             mg/day).

         16. Uncontrolled arterial hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg)
             or clinically significant cardiovascular disease: for example cerebrovascular accident
             (CVA) (in the 6 months prior to randomization), coronaropathy or history of acute
             mycardial infarction (AMI) in the last 6 months, unstable angina, congestive heart
             failure of grade &gt; II of the New York Heart Association (NYHA) or severe heart
             arrhythmias which are not controlled with medication or which can potentially
             interfere with the study treatment.

         17. History or evidence of hemorrhagic diathesis or coagulopathy with bleeding risk.

         18. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abcess
             in the 6 months prior to randomization.

         19. Active infection requiring i.v. antibiotics at the time of randomization.

         20. Unhealed wounds, active peptic ulcer, esophageal varices.

         21. Any other disease, psychological or metabolic alteration, found in the physical or
             laboratory examination, providing reasonable indications for suspecting a disease or
             complaint for which the use of any of the study drugs are contraindicated, or which
             may affect the patient's compliance with the routine procedures of the study or which
             places the patient at a high risk of experiencing complications related to the
             treatment.

         22. Current or recent (within 30 days prior to that start of the study treatment)
             treatment with another drug under investigation or participation in another
             investigation study.

         23. Known hypersensitivity to any of the study drugs or their components.

         24. Hypersensitivity to the products of Chinese hamster ovary cells or to other human or
             humanized recombinant antibodies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>GBG Forschungs GmbH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clínico San Carlos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Provincial de Córdoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Charité</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. W. Schoenegg</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter Krankenhaus</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Bremen</city>
        <zip>28203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen / Kliniken Böblingen</name>
      <address>
        <city>Böblingen</city>
        <zip>71032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berufsausübungsgemeinschaft</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte Evang. Huyssens-Stiftung/Knappschaft</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Hameln</name>
      <address>
        <city>Hameln</city>
        <zip>31785</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxisklinik - Dialysezentrum - Herne</name>
      <address>
        <city>Herne</city>
        <zip>44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-KKH</name>
      <address>
        <city>Köln</city>
        <zip>52428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz Krankenhaus</name>
      <address>
        <city>Limburg</city>
        <zip>65549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincenz und Elisabeth-Hospital</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Bethesda</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik Rheinfelden</name>
      <address>
        <city>Rheinfelden</city>
        <zip>79618</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkolog. Schwerpunktpraxis</name>
      <address>
        <city>Rosenheim</city>
        <zip>83022</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Salzgitter</city>
        <zip>38226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Weinheim</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Reichert und Janssen</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josefs-Hospital</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr.-Horst-Schmidt-Kliniken GmbH</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten</name>
      <address>
        <city>Witten</city>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>3203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Badalona/Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto catalán de Oncología de Barcelona</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xarxa Asistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporación Sanitaria Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrasa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrasa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Barbastro</name>
      <address>
        <city>Barbastro</city>
        <state>Huesca</state>
        <zip>22300</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncológico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Cristina de Badajoz</name>
      <address>
        <city>Badajoz</city>
        <zip>06080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia de Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lérida</name>
      <address>
        <city>Lérida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>MAdrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIOCC Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org/</url>
    <description>Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2007</study_first_posted>
  <results_first_submitted>January 22, 2019</results_first_submitted>
  <results_first_submitted_qc>April 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 10, 2019</results_first_posted>
  <last_update_submitted>April 22, 2019</last_update_submitted>
  <last_update_submitted_qc>April 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endocrine therapy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>breast cancer</keyword>
  <keyword>first-line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A: Endocrine Therapy (ET)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
        </group>
        <group group_id="P2">
          <title>Arm B: ET With Bevacizumab (ET-B)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Treatment not received</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Between November 2007 and August 2011, 380 patients were recruited and randomly assigned to receive ET (189) or ET-B (191). 6 patients, 5 in the ET arm and 1 in the ET-B arm, never received treatment; thus, a total of 374 patients (184 on ET and 190 on ET-B) were evaluable for efficacy and safety.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm A: Endocrine Therapy (ET)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
        </group>
        <group group_id="B2">
          <title>Arm B: ET With Bevacizumab (ET-B)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
            <count group_id="B2" value="190"/>
            <count group_id="B3" value="374"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="39" upper_limit="86"/>
                    <measurement group_id="B2" value="64" lower_limit="38" upper_limit="85"/>
                    <measurement group_id="B3" value="65" lower_limit="38" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) status</title>
          <description>ECOG score runs from 0 to 5, with 0 denoting perfect health and 5 death. 0 – Asymptomatic
– Symptomatic but completely ambulatory
– Symptomatic, &lt;50% in bed during the day
– Symptomatic, &gt;50% in bed, but not bedbound
– Bedbound
– Death</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ECOG 0</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ECOG 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous (neo)adjuvant chemotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Taxanes, anthracyclines, or both</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cyclophosphamide+methotrexate+fluorouracil (CMF)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No previous (neo)adjuvant chemotherapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous (neo)adjuvant endocrine therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Previous (neo)adjuvant therapy: Antiestrogens</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Previous (neo)adjuvant therapy:Aromatase inhibitor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Previous (neo)adjuvant therapy: Both</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No previous (neo)adjuvant endocrine therapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage of disease at study entry</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Locally advanced</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of metastatic sites</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Single</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Visceral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non visceral</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not present</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="132"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Measurable disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Measurable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non measurable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>PFS was defined as the time elapsed from randomization until the date in which the progression of the disease or the death for any reason (whichever occurs first) is documented.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>PFS was defined as the time elapsed from randomization until the date in which the progression of the disease or the death for any reason (whichever occurs first) is documented.</description>
          <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.4" upper_limit="17.5"/>
                    <measurement group_id="O2" value="19.3" lower_limit="16.5" upper_limit="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time elapsed since randomization, until the time in which death occurs for any reason. The patients lost in the follow-up will be censured at the date of the last follow-up.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time elapsed since randomization, until the time in which death occurs for any reason. The patients lost in the follow-up will be censured at the date of the last follow-up.</description>
          <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" lower_limit="38.82" upper_limit="64.75"/>
                    <measurement group_id="O2" value="52.1" lower_limit="35.79" upper_limit="68.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>TTF was defined as the time elapsed since randomization until the date the treatment is discontinued for any reason (progression disease, treatment toxicity or death).</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>TTF was defined as the time elapsed since randomization until the date the treatment is discontinued for any reason (progression disease, treatment toxicity or death).</description>
          <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.31" upper_limit="17.56"/>
                    <measurement group_id="O2" value="15.1" lower_limit="12.66" upper_limit="17.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>ORR to treatment is reflected by a frequency table containing the data of the best overall response (Complete Response, Partial Response,Stable Disease or Progressive Disease) experienced for each patient during treatment (recorded from the start of the treatment until disease progression) per arm.</description>
        <time_frame>2 years</time_frame>
        <population>Only patients with measurable lesions were taken into account</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>ORR to treatment is reflected by a frequency table containing the data of the best overall response (Complete Response, Partial Response,Stable Disease or Progressive Disease) experienced for each patient during treatment (recorded from the start of the treatment until disease progression) per arm.</description>
          <population>Only patients with measurable lesions were taken into account</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Duration (RD)</title>
        <description>RD was defined as the time elapsed from when a partial or complete response is verified until the time in which progression or death occurs.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Only patients with partial or complete response were taken into account</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Response Duration (RD)</title>
          <description>RD was defined as the time elapsed from when a partial or complete response is verified until the time in which progression or death occurs.</description>
          <population>Only patients with partial or complete response were taken into account</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.32" lower_limit="11.19" upper_limit="15.45"/>
                    <measurement group_id="O2" value="17.59" lower_limit="8.9" upper_limit="26.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR)</title>
        <description>CBR was defined as the percentage of patients achieving a Complete Response (CR), a Partial Response (PR) or a stabilization of the disease (SD) &gt; 6 months: the response will be evaluated according to the RECIST criteria. In the patients without measurable disease at the baseline time, the clinical benefit will be defined as the absence of progression &gt; 6 months.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A: Endocrine Therapy (ET)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
          </group>
          <group group_id="O2">
            <title>Arm B: ET With Bevacizumab (ET-B)</title>
            <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR)</title>
          <description>CBR was defined as the percentage of patients achieving a Complete Response (CR), a Partial Response (PR) or a stabilization of the disease (SD) &gt; 6 months: the response will be evaluated according to the RECIST criteria. In the patients without measurable disease at the baseline time, the clinical benefit will be defined as the absence of progression &gt; 6 months.</description>
          <population>Arm A: 189 patients were randomized, but only 184 started treatment due to patient´s wish.
Arm B: 191 patients were randomized, but only 190 started treatment due to patient´s wish.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study treatment, average of 14 months.</time_frame>
      <desc>The adverse events will be recorded throughout the study. The events that are not related with the study medication will be followed up for 30 days and the related ones until their resolution or stabilization; the selected target adverse events, regardless of their causality, will be followed up until their resolution or stabilization, as specified in the protocol. Arm A: 189 patients randomized, but 184 started treatment. Arm B: 191 patients randomized, but 190 started treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm A: Endocrine Therapy (ET)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Fulvestrant</description>
        </group>
        <group group_id="E2">
          <title>Arm B: ET With Bevacizumab (ET-B)</title>
          <description>Endocrine treatment consisting of either letrozole or fulvestrant. Patients will be randomized to receive bevacizumab 15mg/kg i.v. on day 1 every 3 weeks plus endocrine treatment or endocrine treatment as a single agent. The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
Letrozole
Bevacizumab
Fulvestrant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE-NCI 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cardiac infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Inguinal hernia surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Parodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Ulceration of Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Unknown death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cholecystis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cholelitiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Descompensated liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess right breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Erysipela arm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Benzodiapezine intoxication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fracture of Olecranon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Overdose Bevacizumab</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Rigth iliac fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Wound healing complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypochondrium pain by increased transaminase values</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Aseptic necrosis of jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Jaw osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Osteochemonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pain left lower extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Promyelocytic leukemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebellum infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hemi-hyperesthesia right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Ischemic insult</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Syncope vagovagal</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Severe renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Urinary obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain in back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Thrombosis lower leg left</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE-NCI 3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="188" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Liver dysfunction</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fever without neutropenia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Fever without neutropenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocytopenia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Elevated bilirubin</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Elevated liver enzyme (ALT and/or AST)</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Elevated liver enzyme (ALT and/or AST)</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <description>Grade 1-4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
              </event>
              <event>
                <sub_title>Thromboembolic events</sub_title>
                <description>Grade 3-4</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="190"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scientific Director / Medical Lead / Project Manager</name_or_title>
      <organization>Spanish Breast Cancer Research Group</organization>
      <phone>+34916592870</phone>
      <email>geicam@geicam.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

